Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 71610-249

6 FDA label images from Aphena Pharma Solutions - Tennessee, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71610-249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 500 mg (71610 0249 53)

Bottle Label 500 mg (71610 0249 53)
Divalproex sodium 500 mg extended release film-coated tablets packaging label from Aphena Pharma Solutions - Tennessee, LLC. The label indicates a bottle with 60 tablets, storage instructions at controlled room temperature, and manufacturing by Aurobindo Pharma Limited in India. The label includes lot number, barcode, and expiration date.*
FDA Label Image

Aphena Pharma Solutions (TN)

Aphena Pharma Solutions (TN)
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
A cumulative distribution plot comparing percent reduction in CPS rate between Divalproex Sodium Delayed-Release Tablets and placebo. The y-axis shows percentage reduction in CPS rate, ranging from -100% (worsening) to 100% (improvement). The x-axis represents percent of patients from 100% to 0%. The graph uses a solid line for Divalproex Sodium and a dashed line for placebo, illustrating treatment effect distribution.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A graph showing the percentage reduction in CPS Rate (y-axis) against the percentage of patients (x-axis) comparing high dose and low dose Divalproex Sodium delayed-release tablets. The graph indicates improvement or worsening in patients, with high dose and low dose represented by solid and dashed lines, respectively.*
FDA Label Image

Fig-3 (Divalproex Fig3)

Fig-3 (Divalproex Fig3)
A bar graph comparing the effects of Placebo and Divalproex Sodium Extended-Release Tablets. The vertical axis shows a numeric scale from 0.0 to 1.2. The Placebo bar reaches 0.6, while the Divalproex Sodium Extended-Release Tablets bar reaches 1.2, with a statistical significance indicator (p=0.006) marked above the latter bar.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure of Divalproex sodium, showing its polymeric form with repeated units containing sodium carboxylate groups and branched alkyl chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.